Renaissance Technologies
DRUG

Renaissance Technologies’s Bright Minds Biosciences DRUG Stock Holding History

Renaissance Technologies’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,500
Closed -$212K – 3360
2025
Q3 		$212K Buy
+3,500
New +$136K ﹤0.01% 3117
2024
Q1 		– Sell
-11,996
Closed -$17K – 3782
2023
Q4 		$17K Buy
+11,996
New +$17.1K ﹤0.01% 3596
2023
Q3 		– Sell
-2,240
Closed -$6K – 3750
2023
Q2 		$6K Sell
2,240
-3,301
-60% -$9.28K ﹤0.01% 3845
2023
Q1 		$12K Buy
+5,541
New +$18.4K ﹤0.01% 3871

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Renaissance Technologies's DRUG Position: Q4 2025 in Review

Renaissance Technologies sold out of Bright Minds Biosciences (DRUG) in Q4 2025, closing a stake of 3,500 shares — an estimated $212K sold.

Renaissance Technologies first reported a position in DRUG in Q1 2023 and held it in 4 quarters. The position peaked at $212K in Q3 2025. 74 funds tracked by Wall St. Rank hold DRUG as of Q4 2025.

  • Renaissance Technologies reported no remaining Bright Minds Biosciences position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 3,500 Bright Minds Biosciences shares in Q4 2025, an estimated $212K.
  • Renaissance Technologies first reported a position in Bright Minds Biosciences in Q1 2023 and held it in 4 quarters.
  • Renaissance Technologies's Bright Minds Biosciences position peaked at $212K in Q3 2025.
  • 74 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.